Navigating the COVID-19 Therapeutic Landscape: Unveiling Novel Perspectives on FDA-Approved Medications, Vaccination Targets, and Emerging Novel Strategies DOI Creative Commons
Reham F. Barghash, Donato Gemmati, Ahmed M. Awad

et al.

Molecules, Journal Year: 2024, Volume and Issue: 29(23), P. 5564 - 5564

Published: Nov. 25, 2024

Amidst the ongoing global challenge of SARS-CoV-2 pandemic, quest for effective antiviral medications remains paramount. This comprehensive review delves into dynamic landscape FDA-approved repurposed COVID-19, categorized as and non-antiviral agents. Our focus extends beyond conventional narratives, encompassing vaccination targets, repurposing efficacy, clinical studies, innovative treatment modalities, future outlooks. Unveiling genomic intricacies variants, including WHO-designated Omicron variant, we explore diverse categories such fusion inhibitors, protease transcription neuraminidase nucleoside reverse transcriptase, interventions like importin α/β1-mediated nuclear import neutralizing antibodies, convalescent plasma. Notably, Molnupiravir emerges a pivotal player, now licensed in UK. offers fresh perspective on historical evolution COVID-19 therapeutics, from endeavors to latest developments oral anti-SARS-CoV-2 treatments, ushering new era hope battle against pandemic.

Language: Английский

Navigating the COVID-19 Therapeutic Landscape: Unveiling Novel Perspectives on FDA-Approved Medications, Vaccination Targets, and Emerging Novel Strategies DOI Creative Commons
Reham F. Barghash, Donato Gemmati, Ahmed M. Awad

et al.

Molecules, Journal Year: 2024, Volume and Issue: 29(23), P. 5564 - 5564

Published: Nov. 25, 2024

Amidst the ongoing global challenge of SARS-CoV-2 pandemic, quest for effective antiviral medications remains paramount. This comprehensive review delves into dynamic landscape FDA-approved repurposed COVID-19, categorized as and non-antiviral agents. Our focus extends beyond conventional narratives, encompassing vaccination targets, repurposing efficacy, clinical studies, innovative treatment modalities, future outlooks. Unveiling genomic intricacies variants, including WHO-designated Omicron variant, we explore diverse categories such fusion inhibitors, protease transcription neuraminidase nucleoside reverse transcriptase, interventions like importin α/β1-mediated nuclear import neutralizing antibodies, convalescent plasma. Notably, Molnupiravir emerges a pivotal player, now licensed in UK. offers fresh perspective on historical evolution COVID-19 therapeutics, from endeavors to latest developments oral anti-SARS-CoV-2 treatments, ushering new era hope battle against pandemic.

Language: Английский

Citations

1